# Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma

> **NCT00966251** · PHASE1,PHASE2 · TERMINATED · sponsor: **CureTech Ltd** · enrollment: 2 (actual)

## Conditions studied

- Primary Hepatocellular Carcinoma

## Interventions

- **DRUG:** CT-011

## Key facts

- **NCT ID:** NCT00966251
- **Lead sponsor:** CureTech Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was stopped because of slow accrual
- **Last updated:** 2012-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00966251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00966251, "Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00966251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*